Harmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome Treatment
PLYMOUTH MEETING, PA — In a significant development for patients with Prader-Willi syndrome (PWS), Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the initiation of a global Phase 3 registrational …
Harmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome Treatment Read More